FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226248511> ?p ?o ?g. }

• W4226248511 endingPage "e90" @default.
• W4226248511 startingPage "e90" @default.
• W4226248511 abstract "The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting.We conducted a test-negative case-control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19-like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose).The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer-BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or ≥50 years), race and ethnic group, presence of underlying conditions, and level of patient contact. Estimates of vaccine effectiveness were lower during weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose, but confidence intervals overlapped widely.The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world conditions in preventing symptomatic Covid-19 in health care personnel, including those at risk for severe Covid-19 and those in racial and ethnic groups that have been disproportionately affected by the pandemic. (Funded by the Centers for Disease Control and Prevention.)." @default.
• W4226248511 created "2022-05-05" @default.
• W4226248511 creator A5000229952 @default.
• W4226248511 creator A5007110894 @default.
• W4226248511 creator A5009488288 @default.
• W4226248511 creator A5010231082 @default.
• W4226248511 creator A5010374409 @default.
• W4226248511 creator A5011821037 @default.
• W4226248511 creator A5017717374 @default.
• W4226248511 creator A5020866579 @default.
• W4226248511 creator A5021441782 @default.
• W4226248511 creator A5022513906 @default.
• W4226248511 creator A5024358117 @default.
• W4226248511 creator A5025935462 @default.
• W4226248511 creator A5028308462 @default.
• W4226248511 creator A5029224381 @default.
• W4226248511 creator A5029937352 @default.
• W4226248511 creator A5033082758 @default.
• W4226248511 creator A5036945319 @default.
• W4226248511 creator A5037111149 @default.
• W4226248511 creator A5038255684 @default.
• W4226248511 creator A5041342651 @default.
• W4226248511 creator A5047729879 @default.
• W4226248511 creator A5052625968 @default.
• W4226248511 creator A5053304927 @default.
• W4226248511 creator A5056287146 @default.
• W4226248511 creator A5061360456 @default.
• W4226248511 creator A5062002754 @default.
• W4226248511 creator A5063738706 @default.
• W4226248511 creator A5064280673 @default.
• W4226248511 creator A5065119926 @default.
• W4226248511 creator A5065282470 @default.
• W4226248511 creator A5069499802 @default.
• W4226248511 creator A5072063787 @default.
• W4226248511 creator A5074256851 @default.
• W4226248511 creator A5078426618 @default.
• W4226248511 creator A5079086152 @default.
• W4226248511 creator A5081870847 @default.
• W4226248511 creator A5082586023 @default.
• W4226248511 creator A5083262012 @default.
• W4226248511 creator A5083632547 @default.
• W4226248511 creator A5084949326 @default.
• W4226248511 creator A5087653992 @default.
• W4226248511 creator A5088369222 @default.
• W4226248511 creator A5089255560 @default.
• W4226248511 creator A5089727275 @default.
• W4226248511 creator A5089795238 @default.
• W4226248511 date "2021-12-16" @default.
• W4226248511 modified "2023-10-17" @default.
• W4226248511 title "Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel" @default.
• W4226248511 cites W2921495327 @default.
• W4226248511 cites W3108542354 @default.
• W4226248511 cites W3111255098 @default.
• W4226248511 cites W3114735216 @default.
• W4226248511 cites W3129580280 @default.
• W4226248511 cites W3131688063 @default.
• W4226248511 cites W3133128009 @default.
• W4226248511 cites W3136431856 @default.
• W4226248511 cites W3141986261 @default.
• W4226248511 cites W3157162195 @default.
• W4226248511 cites W3158235488 @default.
• W4226248511 cites W3158706520 @default.
• W4226248511 cites W3159191704 @default.
• W4226248511 cites W3159689317 @default.
• W4226248511 cites W3161861537 @default.
• W4226248511 cites W3165010107 @default.
• W4226248511 cites W3167220489 @default.
• W4226248511 cites W3169993409 @default.
• W4226248511 cites W3180807731 @default.
• W4226248511 cites W3195990721 @default.
• W4226248511 cites W4205483821 @default.
• W4226248511 doi "https://doi.org/10.1056/nejmoa2106599" @default.
• W4226248511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34551224" @default.
• W4226248511 hasPublicationYear "2021" @default.
• W4226248511 type Work @default.
• W4226248511 citedByCount "175" @default.
• W4226248511 countsByYear W42262485112021 @default.
• W4226248511 countsByYear W42262485112022 @default.
• W4226248511 countsByYear W42262485112023 @default.
• W4226248511 crossrefType "journal-article" @default.
• W4226248511 hasAuthorship W4226248511A5000229952 @default.
• W4226248511 hasAuthorship W4226248511A5007110894 @default.
• W4226248511 hasAuthorship W4226248511A5009488288 @default.
• W4226248511 hasAuthorship W4226248511A5010231082 @default.
• W4226248511 hasAuthorship W4226248511A5010374409 @default.
• W4226248511 hasAuthorship W4226248511A5011821037 @default.
• W4226248511 hasAuthorship W4226248511A5017717374 @default.
• W4226248511 hasAuthorship W4226248511A5020866579 @default.
• W4226248511 hasAuthorship W4226248511A5021441782 @default.
• W4226248511 hasAuthorship W4226248511A5022513906 @default.
• W4226248511 hasAuthorship W4226248511A5024358117 @default.
• W4226248511 hasAuthorship W4226248511A5025935462 @default.
• W4226248511 hasAuthorship W4226248511A5028308462 @default.
• W4226248511 hasAuthorship W4226248511A5029224381 @default.
• W4226248511 hasAuthorship W4226248511A5029937352 @default.
• W4226248511 hasAuthorship W4226248511A5033082758 @default.
• W4226248511 hasAuthorship W4226248511A5036945319 @default.
• W4226248511 hasAuthorship W4226248511A5037111149 @default.

• next